| | | | | | | | | | |
|
|
| Dockets Entered
On June 28, 2006
Table of Contents
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
| 1995V-0105
|
| Laser Light Show
|
|
|
| 1996V-0432
|
| Laser light show application
|
|
|
| 2002V-0183
|
| Laser Light Show
|
|
|
| 2003V-0426
|
| Laser Light Show
|
|
|
| 2005P-0008
|
| simvastatin tablets 5mg, 10mg, 20mg, and 40 mg
|
|
|
| 2005P-0046
|
| removal of patent listings by reinserting the info in the orange book and maintain the listing until Ranbaxy's term of exclusivity has elapsed
|
|
|
| 2005P-0072
|
| Withholding of safety information regarding risks of Steven s Johnson Syndrome and Toxic Epidermal Necrolysis Associated with Ibuprofen products
|
|
|
| 2005P-0323
|
| Immediately remove Adderall and Adderall XR from the market for safety reasons
|
|
|
| 2005P-0411
|
| Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
|
|
|
| 2005P-0509
|
| Evaluation the warning to Consumers that Psychosis Is a possible adverse effect of Keppra (levetiracetam)
|
|
|
| 2005V-0368
|
| Projector for a Laser Light Show for Flare F1-1104; Flint: F2-0104; Firefly : F3-0905
|
|
|
| 2006D-0254
|
| Guidance for Industry: Analytical Methods Description for Type C Medicated Feeds
|
|
|
| 2006D-0268
|
| Guidance for Industry: Development of Preventive HIV Vaccines for Use in Pediatric Populations
|
|
|
| 2006N-0133
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Evaluation of Variations in Content and Format of the Brief Summary in Direct-to-Consumer (DTC) Print Adver
|
|
|
|
|
|
| 2006P-0001
|
| Date of Approval for Lunesta (Eszopiclone) Tablets
|
|
|
| 2006P-0047
|
| Refrain from Approval any ANDA for Celestone Soluspan
|
|
|
| 2006P-0241
|
| Appeal District Court Civil Action No. 05-1838 (RWR) and deny the citzen petitions of Ivax and Ranbaxy
|
|
|
| 2006P-0258
|
| Immediately approve ANDA No. 77-837 upon the June 23, 2006 patent expiration of U.S. Patent No. 4,444,784
|
|
|
| 2006V-0111
|
| Projector for a Laser Light Show
|
|
|
| 2006V-0153
|
| Variance for Hair Removal System
|
|
|
| 2006V-0155
|
| Laser Light Show
|
|
|
| 2006V-0248
|
| Laser Light Show
|
|
|
| 1995V-0105
|
| Laser Light Show
|
|
|
| VRA 6
|
| FDA/CDRH to Stellar Designs, Inc.
|
| Vol #:
|
| 1
|
|
|
| 1996V-0432
|
| Laser light show application
|
|
|
| VRA 3
|
| FDA/CDRH to N Effect Production
|
| Vol #:
|
| 1
|
|
|
| 2002V-0183
|
| Laser Light Show
|
|
|
| CR 1
|
| FDA/DDM to Funzalosound
|
| Vol #:
|
| 1
|
|
|
| 2003V-0426
|
| Laser Light Show
|
|
|
| VRA 3
|
| FDA/CDRH to Celebration City
|
| Vol #:
|
| 1
|
|
|
| 2005P-0008
|
| simvastatin tablets 5mg, 10mg, 20mg, and 40 mg
|
|
|
| LET 3
|
| FDA/CDER to Ivax Pharmaceuticals, Inc.
|
| Vol #:
|
| 2
|
|
| | | | | | | | |
|
|
| C 13820
|
| Mrs. J. Gaughan
|
| Vol #:
|
| 159
|
|
|
| C 13821
|
| G. Stevens
|
| Vol #:
|
| 159
|
|
|
| C 13822
|
| P. Lee
|
| Vol #:
|
| 159
|
|
|
| C 13823
|
| J. G. Gervais
|
| Vol #:
|
| 159
|
|
|
| C 13824
|
| C. Jantzen
|
| Vol #:
|
| 159
|
|
|
| C 13825
|
| C. Van Poznak
|
| Vol #:
|
| 159
|
|
|
| C 13826
|
| K. LaCroix
|
| Vol #:
|
| 159
|
|
|
| C 13827
|
| M. Robinson
|
| Vol #:
|
| 159
|
|
|
| C 13828
|
| L. Sinnwell
|
| Vol #:
|
| 159
|
|
|
| C 13829
|
| J. Anderson
|
| Vol #:
|
| 159
|
|
|
| C 13830
|
| K. Yonkers
|
| Vol #:
|
| 159
|
|
|
| C 13831
|
| K. Kendall
|
| Vol #:
|
| 159
|
|
|
| C 13832
|
| L. Wilson
|
| Vol #:
|
| 159
|
|
|
| C 13833
|
| S. Wanamaker
|
| Vol #:
|
| 159
|
|
|
| C 13834
|
| J. Hunerberg
|
| Vol #:
|
| 159
|
|
|
| C 13835
|
| K. S. Fabian
|
| Vol #:
|
| 159
|
|
|
| C 13836
|
| J. Berman
|
| Vol #:
|
| 159
|
|
|
| C 13837
|
| S.C. Skolnikoff, Ph.D.
|
| Vol #:
|
| 159
|
|
|
| C 13838
|
| J. Smith
|
| Vol #:
|
| 159
|
|
|
| 2005P-0509
|
| Evaluation the warning to Consumers that Psychosis Is a possible adverse effect of Keppra (levetiracetam)
|
|
|
| LET 1
|
| FDA/CDER to Warren Rucker
|
| Vol #:
|
| 1
|
|
|
| 2005V-0368
|
| Projector for a Laser Light Show for Flare F1-1104; Flint: F2-0104; Firefly : F3-0905
|
|
|
| VRA 1
|
| FDA/CDRH to Prismatic Magic LLC
|
| Vol #:
|
| 1
|
|
|
| 2006D-0254
|
| Guidance for Industry: Analytical Methods Description for Type C Medicated Feeds
|
|
|
| GDL 1
|
| Guidance
|
| Vol #:
|
| 1
|
|
|
| NAD 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2006D-0268
|
| Guidance for Industry: Development of Preventive HIV Vaccines for Use in Pediatric Populations
|
|
|
| C 1
|
| R. Reinhard
|
| Vol #:
|
| 1
|
|
|
| 2006N-0133
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Evaluation of Variations in Content and Format of the Brief Summary in Direct-to- Consumer (DTC) Print Adver
|
|
|
|
|
|
| C 3
|
| AstraZeneca Pharmaceuticals, LP
|
| Vol #:
|
| 1
|
|
|
| 2006P-0001
|
| Date of Approval for Lunesta (Eszopiclone) Tablets
|
|
|
| C 1
|
| D. Lowe
|
| Vol #:
|
| 1
|
|
| | | | | | | | |
|
|
| 2006P-0047
|
| Refrain from Approval any ANDA for Celestone Soluspan
|
|
|
| PAV 1
|
| FDA/CDER to SPEC Pharma
|
| Vol #:
|
| 1
|
|
|
| 2006P-0241
|
| Appeal District Court Civil Action No. 05-1838 (RWR) and deny the citzen petitions of Ivax and Ranbaxy
|
|
|
| LET 1
|
| FDA/CDER to Pollack PC
|
| Vol #:
|
| 1
|
|
|
| 2006P-0258
|
| Immediately approve ANDA No. 77-837 upon the June 23, 2006 patent expiration of U.S. Patent No. 4,444,784
|
|
|
| LET 1
|
| FDA/CDER to Pollack PC
|
| Vol #:
|
| 1
|
|
|
| 2006V-0111
|
| Projector for a Laser Light Show
|
|
|
| VRA 1
|
| FDA/CDRH to Aurora Projections
|
| Vol #:
|
| 1
|
|
|
| 2006V-0153
|
| Variance for Hair Removal System
|
|
|
| VRA 2
|
| FDA/CDRH to Palomar Medical Technologies, Inc.
|
| Vol #:
|
| 1
|
|
|
| 2006V-0155
|
| Laser Light Show
|
|
|
| VRA 1
|
| FDA/CDRH to Club Rabie, Inc
|
| Vol #:
|
| 1
|
|
|
| 2006V-0248
|
| Laser Light Show
|
|
|
| VRA 1
|
| FDA/CDRH to Independence High-SpaceScience Tech Magnet
|
| Vol #:
|
| 1
|
|